It targets multiple pathways underlying a migraine attack ... The latest FDA nod for Symbravo diversifies Axsome’s commercial drug portfolio. The company currently markets Auvelity (AXS-05 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback